Introduction
efficacious in most patients, there are situations when an oral preparation may be preferred, such as in young children and patients with nasal problems. Since 1983 The synthetic vasopressin analogue, 1-deamino-8--arginine (DDAVP) has been the standard treatment for it has been demonstrated that orally administered DDAVP can be absorbed from the gastrointestinal tract central diabetes insipidus for over 20 years [1] . Although the commonly used intranasal (IN) preparations, and result in a dose-dependent antidiuretic response in dogs and humans [ 3, 4] . DDAVP tablets have been employing the rhinyle or spray method [2 ] are highly registered for clinical use in Sweden since 1987, but Study protocol have only recently become more widely available. In children with central diabetes insipidus [ 5] , the pharmOne week prior to hospitalization for this study, patients were asked to record their daily urine output on at least acokinetics and pharmacodynamics of oral DDAVP have been well studied and its long-term efficacy and 2 days of maintenance therapy with IN DDAVP and random plasma and urine osmolalities were checked. safety documented [ 6] . In adults, the pharmacokinetics and pharmacodynamics of oral vs IN DDAVP have
The subsequent follow up was divided into acute and chronic phases. For the acute phase, all patients were only been studied in normal subjects [7 ] . Although in one study [8 ] , similar pharmacokinetics were found in hospitalized in the Metabolic Ward for 1 week (starting on Day 0 ), during which they were studied according patients with central diabetes insipidus and normal subjects following the 200 mg oral dose, apparently the to a fixed schedule as described in Table 2 . Maintenance IN DDAVP was stopped 24 h prior to Day 1 and no magnitude and duration of antidiuresis were dissimilar. Furthermore, in normal subjects or patients, there are DDAVP was administered on Day 2. On Days 1 and 3, the pharmacokinetics and antidiuretic activity (as repno published data comparing the pharmacodynamics of all three commonly used oral DDAVP preparations resented by changes in urine flow rate and osmolality) of a single dose of IN and oral (tablet form) DDAVP (containing 100, 200 and 400 mg). In adults, moreover, there is very little information on the long-term safety 20 mg and 200 mg respectively, were studied. From Days 4 to 6, a dose-ranging study was carried out using single of oral DDAVP; one case report involved only three patients followed for up to 45 months [ 9] and another oral tablets of DDAVP 100, 200 and 400 mg respectively -in order to determine the minimum dose at described eight patients whose mean follow up was only 5 months [10 ] .
which adequate antidiuresis could be achieved for approximately 8 h. We report here the pharmacokinetics and acute dosedependent antidiuretic effects of IN and oral DDAVP On Days 1 and 3, 5 ml blood samples were collected in vacutainer tubes containing potassium EDTA before in patients with central diabetes insipidus as well as a prospective study of the long-term efficacy, dosage and at 20, 40, 60, 90, 120, 180, 240, 360 and 480 min after DDAVP administration. The samples were centrirequirement and safety of oral DDAVP.
fuged, freshly separated and the plasma stored at −70°C for later analysis of the DDAVP concentration. Hourly urine output, urine and plasma osmolalities were measured before and at 1, 2, 4, 6 and 8 h after Methods DDAVP administration. In addition, on Days 4 to 6, urine osmolality was also measured at 12 h and urine Ten Chinese adults with central diabetes insipidus, aged 36.4±6.7 years (mean±s.d.) and weighing 63.9±11.1 kg, output was recorded 4 hourly up to 24 h. Plasma osmolality was measured before and at 4 h only. Each whose clinical data are summarized in Table 1 , participated in the study. All had satisfactory control of their patient was discharged from hospital on Day 7 taking a dose of oral DDAVP (2-3 times/day) depending on disease on IN DDAVP (Ferring Pharmaceuticals, Malmo, Sweden) for at least 1 year prior to the study, the results of the dose-ranging study. During the chronic phase (outpatient follow-up), eight of them using the rhinyle and two, the nasal spray. All were studied after written informed consent and patients were asked to record daily body weight and chart their fluid intake and urine output on at least 2 according to a protocol approved by the Ethics Committee of the University of Hong Kong. days per week for the first 4 weeks. Unless otherwise indicated, complete blood counts, plasma electrolytes, 0.85-0.99) for the corresponding log concentration/time plots. An HP calculator and 'curve fitting' standard renal and liver function tests, as well as plasma and urine osmolalities were checked and dosage adjustments pack programme SD-O3A were used for the calculation. Statistical analysis was performed using two-way made as necessary at weekly intervals for 4 weeks and at 3 monthly intervals thereafter. Patients were asked analysis of variance and Student's two-tailed paired ttest after the data were ascertained to be normally to record their 24-h urine output on one day shortly before each 3 month clinic visit.
distributed using the Lilliefors test. Wilcoxon matched pair signed-rank test was used to compare the duration of antidiuresis, which was not normally distributed.
Pearson's correlation analysis was employed for Assays assessing the relationship between DDAVP dose and effects. The level of significance was set at P<0.05. Plasma samples for DDAVP assay were transported in dry ice from Hong Kong to Sweden and the concentrations measured by radioimmunoassay at the laboratory of Ferring Pharmaceuticals, using a modification of the method described by Lundin et al. [11] . The Results samples were extracted with acetone/petroleum ether prior to analyses; the recovery of DDAVP after Pharmacokinetics of DDAV P extraction being 97.7% and 98.9% at 5 and 10 pmol l−1 respectively. Monoiodinated DDAVP was prepared
The plasma concentrations of DDAVP at various intervals after DDAVP 20 mg IN or 200 mg oral are by the chloramine-T method and immediately purified by reversed phase chromatography. The antiserum shown in Figure 1a . Plasma DDAVP concentration was undetectable (<2.34 pmol l−1) in all patients before employed was developed according to the method of Sofroniew et al.
[ 12] and showed 0.03% cross-reactivity DDAVP administration. It became detectable in all patients 20 and 20-60 min respectively following IN with AVP. The minimum quantifiable concentration of the assay was 2.34 pmol l−1. All samples of each patient and oral administration. The C max and t max for the two DDAVP preparations are summarized in Table 3 . The were included in the same assay. Mean intra-and interassay coefficients of variation were 7.4% and 12.4% mean elimination half-life (t 1/2,z ) was 2.2 h and 2.0 h after IN and oral administration respectively. Assuming respectively.
Plasma and urine osmolalities were determined by first order absorption and elimination, the mean calculated equidose IN/oral AUC ratio was 1516. freezing point depression using the Advanced MicroOsmometer (Advanced Instruments, Inc., Massachusetts, Patient 8 had plasma DDAVP levels comparable with those of the other patients following IN DDAVP, but USA). Plasma electrolytes, renal and liver function tests (urea, creatinine, liver enzymes. albumin and bilirubin following oral DDAVP on Day 3, plasma DDAVP was undetectable except at 3 and 4 h post dosing, when levels) were measured on the Ektachem 500 analyser using the dry-film chemistry technology from Kodak levels of 11.2 pmol l−1 and 8.6 pmol l−1 were encountered. Her urine osmolality at 2 h was only 93 (Eastman Kodak, Rochester, New York, USA). mosm kg−1 but on Day 5, (despite similar baseline values), it was 607 mosm kg−1 within 2 h of taking a similar dose. This suggested possible erratic and inconPharmacokinetic calculations and statistical analysis sistent absorption on Day 3 which was probably not representative of her usual response to oral DDAVPAfter corresponding treatments in each patient, the maximum DDAVP concentration (C max ) encountered as attested to by her much better antidiuretic responses on days 4-6. Thus, her data were excluded from the and the time at which this occurred (t max ) were recorded. (Figure 1b) was found between the four dosage forms until 4 h after administration, when a higher osmolality was achieved with IN 20 mg (P<0.05 vs all oral doses). From 4 to 8 h after drug administration, urine osmolality was lower with the 100 mg oral dose than with all other doses (P<0.005) but the corresponding differences associated with the other three dosage forms were neither clinically nor statistically significant. For the difference in mean urine osmolality between the 200 and 400 mg doses, 95% confidence intervals were (−32.2, 49.2), (−98.2, 45.0) and (−244.2, 30.2) at 4, 6 and 8 h respectively (P>0.1 for the difference at all three times points). Converse changes in urine flow rate ( Figure 1c) were also evident. From 4 to 8 h, the effect was smaller with the 100 mg oral dose than with the other dosage forms (P<0.005), but there were no clinically or statistically significant differences between corresponding changes in urine flow following the 20 mg IN, and 200 and 400 mg oral doses. For the difference in mean urine flow rate between the 200 and 400 mg doses, 95% confidence intervals were (−6.72, 9.32), (−7.04, 8.04) and (−9.65, 58.45) at 4, 6 and 8 h respectively (P>0.1 at all 3 time points).
Changes in urine osmolality (up to 12 h) and urine flow rate (up to 24 h) indicated a dose-dependent antidiuretic response to oral DDAVP (Table 4 ) . There was a positive correlation between oral DDAVP dose and the duration of antidiuresis, defined as the total duration of having either a urine osmolality Á400 mosm kg−1 or a urine flow rate ∏100 ml h−1 (P<0.001, n=30, r=0.64 and r=0.62 respectively). There was a weak positive correlation between maximum urine osmolality and DDAVP dose (r=0.362, P<0.05). However, increasing the dosage from 200 mg to 400 mg (mean±s.e.mean) and 425±52 ml h−1 for Day 0 and L ong-term follow-up study The dosage requirement of oral DDAVP during the 1 year study is shown in Day 2 respectively (P=0.73).
As shown in Figure 1b and 1c, following all doses of found between the IN and oral doses required. As and the findings in patient 8 also suggest day to day variations in absorption in the same individual. Large shown in Table 5 , satisfactory plasma and urine osmolalities were maintained throughout the study period, individual variations in the absorption of DDAVP following oral administration have also been observed without any need for dosage adjustment after the first month. Compared with findings on IN DDAVP, plasma in children with central diabetes insipidus [5 ] . The mean plasma half-life of 120 min was similar to the figure of and urine osmolalities showed no significant difference after the change to oral DDAVP therapy, whereas there 126 min reported in a British study [8] . The oral/IN AUC ratio was calculated to be 1516, somewhat less was a lower urine flow rate after 1 month (P<0.05).
than the ratio of 1525 reported for normal adults in Sweden [7 ] . In that study, mean AUCs for IN and more especially for oral DDAVP were smaller than the Side-effects and laboratory safety profile corresponding values in our patients, even after crude corrections for mean body weights. Furthermore, after The tablets were well tolerated and all patients preferred to continue on oral DDAVP after completion of the taking 200 mg orally, plasma DDAVP concentration became detectable in all nine of our patients but study. No significant changes in complete blood count, plasma creatinine and electrolytes were observed. A remained undetectable in two of the eight subjects. As to whether these finding suggest real inter-ethnic transient asymptomatic increase in plasma aspartate aminotransferase (AST) to Átwo times the upper difference in pharmacokinetics due to better gastrointestinal absorption of DDAVP in Chinese or other factors normal range (33 iu l−1 for men and 28 iu l−1 for women), which reverted to baseline levels despite remains unclear. Whereas, such differences have been reported with other drugs [13 ] , this study did not continuation of oral DDAVP, was noted in patients 1 and 8 (Table 1 ) . Both had pre-existing elevated AST involve prospective comparison with Caucasian patients, the sample size was small and there was considerable values. In patient 1, plasma AST levels at baseline, 1 week (peak level), 2 weeks and 1 year were 62, 99, 47 interindividual variation. Orally, our patients appeared to need smaller multiples of their respective IN DDAVP and 46 iu l−1 respectively. In patient 8, plasma AST levels at baseline, 4 weeks (peak level), 8 weeks and 1 dosages (17-80; mean 40) than reported for Italian patients (40-60) [ 9] but larger than those recorded in year were 30, 59, 29 and 23 iu l−1 respectively. No other change in liver function test was observed. Both were a British study (7.5-30; mean 15 ) [10] . This is the first report (a) comparing the pharmacodynon-drinkers and had no serological markers of active or chronic hepatitis A, B or C.
namics of 100, 200 and 400 mg, the three commonly used oral doses in patients with central diabetes insipidus and (b) detailing the pharmacodynamics of 400 mg oral doses of DDAVP in adults. The doses were chosen according to previous clinical experience which sugDiscussion gested that both in adults [10 ] and children [14, 15] to obtain adequate therapeutic effects usually requires Oral DDAVP was well absorbed in our patients resulting in maximum plasma DDAVP levels one and a 100 mg or more. The duration of antidiuresis and to a lesser extent, the maximum urine osmolality were shown half hours after drug administration, in agreement with published data in healthy adults [7, 8 ] . There were to be dose dependent. The duration of antidiuretic activity following 100 mg was significantly shorter than considerable individual variations in pharmacokinetics, after the two higher doses, although the maximum urine studies [6, 10 ] , there have been isolated case reports [16] . osmolality was only slightly lower. There was no clinically significant improvement in the magnitude of
In conclusion, for the long-term treatment of adult patients with central diabetes insipidus, we have found antidiuresis when the dose was increased from 200 to 400 mg. However, the trend towards an increased oral DDAVP to be a safe and efficacious alternative to IN preparations and is preferred by the end-user. It is duration of action with the 400 mg preparation may be of clinical relevance if the patient wishes to decrease the clearly advantageous in patients who have difficulty with the inhalation therapy, such as those at the frequency of administration. The rapid rise in urine osmolality in the second hour after the 200 mg dose extremes of age, the mentally or physically handicapped, those with chronic allergic rhinitis and patients with correlated well with the rise in plasma DDAVP level. Although the DDAVP AUC after 20 mg IN was almost nasal packing following transsphenoidal surgery. Furthermore, as the tablets are stable at room temperatwice that following 200 mg orally, the maximum mean urine osmolality at 4 h was only marginally higher, and ture while the IN solution requires refrigeration, oral therapy may be preferred in places with hot climate like there was no statistically significant difference in respective mean urine flow rates for up to 8 h.
Hong Kong. Most adult patients with central diabetes insipidus can be satisfactorily controlled on 300 to Most Chinese patients with central diabetes insipidus can attain adequate antidiuresis with IN DDAVP 600 mg per day (in two to three divided doses). In view of the large individual variations in pharmacokinetics dosages of not more than 10 mg every 8 h. Considering the 16-fold greater bioavailability (AUC) via the latter and the lack of correlation between the oral and IN dose requirement, weekly outpatient dosage adjustment route, it may be surmised that substitution with 200 mg oral doses should suffice. Figure 1 actually confirms that according to plasma and urine osmolalities and home monitoring of urine output is recommended during the a single oral dose of 200 mg produces a sustained discernible effect lasting at least 8 h. It also illustrates first month of oral therapy with DDAVP. that there is a time lag of about 2 h between the
